ACADIA Pharmaceuticals Inc (ACAD) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.
Over the past 4 years, ACADIA Pharmaceuticals Inc has achieved a revenue compound annual growth rate (CAGR) of 68.6%.
Historical revenue and profitability trends for ACADIA Pharmaceuticals Inc
The chart above illustrates ACADIA Pharmaceuticals Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of ACADIA Pharmaceuticals Inc's business.
How efficiently ACADIA Pharmaceuticals Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue ACADIA Pharmaceuticals Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project ACADIA Pharmaceuticals Inc to continue growing earnings in the coming year. The consensus analyst rating is 3.95 based on 20 analysts.
Based on our comprehensive analysis, ACADIA Pharmaceuticals Inc (ACAD) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of ACADIA Pharmaceuticals Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how ACADIA Pharmaceuticals Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: ACAD Valuation, ACAD Dividend, ACAD Financial Health
Compare: ACAD vs AAPL, ACAD vs MSFT, ACAD vs GOOGL